CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
The last earnings update was 42 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
CymaBay Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
CymaBay Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
CymaBay Therapeutics's earnings are expected to grow significantly at over 20% yearly.
CymaBay Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
CymaBay Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
CymaBay Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
CymaBay Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
CymaBay Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
CymaBay Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
CymaBay Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Sujal A. Shah has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah served as an Interim Chief Executive Officer and Interim President of Cymabay Therapeutics, Inc, from March 2017 to November 6, 2017 and as its Chief Financial Officer from December 6, 2013 to April 27, 2017 and as its Principal Financial & Accounting Officer until April 27, 2017. Mr. Shah served as an Acting Chief Financial Officer of Cymabay Therapeutics from June 27, 2012 to December 6, 2013. From 2010 to 2012, he served as a Director of Health Care Investment Banking Group for Citigroup. From 2004 to 2010, Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. He has been a Director of Cymabay Therapeutics, Inc., since April 25, 2017. Mr. Shah holds an MBA from Carnegie Mellon University - Tepper School of Business in 2004, an MS from Northwestern University in Biomedical Engineering in 1997 and a BS in Biomedical Engineering.
Sujal's compensation has been consistent with company performance over the past year, both up more than 20%.
Sujal's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the CymaBay Therapeutics management team is about average.
Vice President of Finance
Senior VP & Chief Scientific Officer
General Counsel & Corporate Secretary
Chief Medical Officer
Chief Regulatory & Compliance Officer
Vice President of Human Resources
Senior Vice President of Business Development
Senior Vice President of Manufacturing & Nonclinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the CymaBay Therapeutics board of directors is about average.
Board of Directors
Kurt von Emster
Member of Clinical Advisory Board and Member of Scientific Advisory Board
Read This Before Selling CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares
So we'll take a look at whether insiders have been buying or selling shares in CymaBay Therapeutics, Inc. … See our latest analysis for CymaBay Therapeutics The Last 12 Months Of Insider Transactions At CymaBay Therapeutics In the last twelve months, the biggest single purchase by an insider was when President Sujal Shah bought US$65k worth of shares at a price of US$6.54 per share. … NasdaqGS:CBAY Recent Insider Trading, May 24th 2019 CymaBay Therapeutics is not the only stock that insiders are buying.
CymaBay Therapeutics (NASDAQ:CBAY) Shareholders Have Enjoyed A Whopping 445% Share Price Gain
Because CymaBay Therapeutics is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Does CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Have A Volatile Share Price?
(NASDAQ:CBAY), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Why Fundamental Investors Might Love CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … Looking at the company as a whole, as a potential stock investment, I believe CBAY has a lot to offer.
Read This Before Selling CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares
The Last 12 Months Of Insider Transactions At CymaBay Therapeutics. … President Sujal Shah made the biggest insider purchase in the last 12 months … Even though the purchase was made at a significantly lower price, we still think insider buying is a positive
What does CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) Balance Sheet Tell Us About Its Future?
(NASDAQ:CBAY), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is CBAY right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding
CymaBay Therapeutics Inc (NASDAQ:CBAY): What Does Its Beta Value Mean For Your Portfolio?
If you're interested in CymaBay Therapeutics Inc (NASDAQ:CBAY), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Breakeven On The Horizon For CymaBay Therapeutics Inc (NASDAQ:CBAY)
CymaBay Therapeutics Inc's (NASDAQ:CBAY):. … CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. … The US$807.48m market-cap posted a loss in its most recent financial year of -US$27.56m and a latest trailing-twelve-month loss of -US$39.21m leading to an even wider gap between loss and breakeven.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.